Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | DAO | P14920 | 5/20 | 0.41 |
| ▸ | PGR | P06401 | 8/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12794217 | 0.86 | POLB (0.51) | POLBDAOPGRKIF11ALDH1A1 | |
| SCHEMBL12794256 | 0.78 | POLB (0.56) | POLBDAOPGR | |
| SCHEMBL3146700 | 0.78 | DAO (0.58) | POLBDAOPGRCYP3A4CYP2B6 | |
| SCHEMBL1496451 | 0.78 | POLB (0.56) | POLBDAOPGRALDH1A1HPGD | |
| SCHEMBL15468282 | 0.78 | KIF11 (0.44) | POLBDAOKIF11ALDH1A1 | |
| SCHEMBL12793646 | 0.78 | DAO (0.67) | POLBDAOPGRALDH1A1HPGD | |
| SCHEMBL12794017 | 0.78 | POLB (0.56) | POLBDAOPGRALDH1A1HPGD | |
| SCHEMBL12792523 | 0.75 | DAO (0.63) | POLBDAOPGRALDH1A1HPGD | |
| SCHEMBL12792847 | 0.74 | POLB (0.55) | POLBDAOPGRALDH1A1HPGD | |
| SCHEMBL798322 | 0.74 | POLB (0.51) | POLBDAOPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK2, CDK1, CDK3 | POLB 1298/4885DAO 1267/4885PGR 2874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.